• webinar de-risking biosimilar programs

On-Demand Webinar | De-risking biosimilar programs: Tackling biosimilarity challenges  

Regulatory focus on interchangeability is making early alignment of protein quality attributes with the originator's profile more critical than ever. This webinar explores how a highly efficient, data-driven approach to cell line development can help you meet these demands without slowing down your timeline. 

Using a case study of a biosimilar to a blockbuster biologic, we demonstrate how a comprehensive cell line development approach combines automated clone screening, advanced data modeling, and an early focus on critical quality attributes (CQAs). See how simultaneous process and media optimization, guided by a design of experiments (DoE) approach, helped increase titer and optimize the N-glycan profile — and how several rounds of fine-tuning helped identify a lead clone and ensure a process ready for scale-up. 

 

What You Will Learn:

  1. Learn how advanced clone screening and DoE can accelerate biosimilar cell line development. 
  2. Discover strategies for controlling CQAS to support regulatory comparability. 
  3. Explore a real-world case study for de-risking development toward commercialization. 

Please Complete the Form

Complete Form to Watch

Meet Our Experts

Christiane Hartmann

Scientist Operations

Christiane Hartmann, PhD, is a scientist with more than eight years of experience in the biotechnology and pharmaceutical industries. She works at Sartorius as a scientist specializing in customer-focused cell line development projects. In this role, she is the scientific lead within project teams, conducting data evaluations and engaging in in-depth scientific discussions with clients.